Evidence map›Paper›PMID 38315011›Full record

ArticleMicrobiology spectrum2024

Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.

Ighor Arantes, Marcelo Gomes, Kimihito Ito, Sharbilla Sarafim, Tiago Gräf, Fabio Miyajima, Ricardo Khouri, Felipe Cotrim de Carvalho, Walquiria Aparecida Ferreira de Almeida, Marilda Mendonça Siqueira and 4 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. A comprehensive analysis of the SARS-CoV-2 omicron variant in Tocantins State, Brazil, and tracing the spread of the XBB.1.18.1 lineage.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Ighor ArantesLaboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.ORCID 0000-0002-4131-5338
Marcelo GomesGrupo de Métodos Analíticos em Vigilância Epidemiológica, Fiocruz, Rio de Janeiro, Brazil.
Kimihito ItoInternational Institute for Zoonosis Control, Hokkaido University, Hokkaido, Japan.
Sharbilla SarafimLaboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Tiago GräfLaboratório de Virologia Molecular, Instituto Carlos Chagas, Fiocruz, Curitiba, Brazil.
Fabio MiyajimaFiocruz, Fortaleza, Brazil.ORCID 0000-0002-1347-4825
Ricardo KhouriInstituto Gonçalo Moniz, Fiocruz, Salvador, Brazil.
Felipe Cotrim de CarvalhoDepartamento do Programa Nacional de Imunizações, Coordenação-Geral de Vigilância das doenças imunopreveníveis, Secretaria de Vigilância em saúde e ambiente, Brasília, Brazil.
Walquiria Aparecida Ferreira de AlmeidaDepartamento do Programa Nacional de Imunizações, Coordenação-Geral de Vigilância das doenças imunopreveníveis, Secretaria de Vigilância em saúde e ambiente, Brasília, Brazil.
Marilda Mendonça SiqueiraLaboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Paola Cristina ResendeLaboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Felipe Gomes NavecaLaboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Gonzalo BelloLaboratório de Arbovírus e Vírus Hemorrágicos, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.ORCID 0000-0002-2724-2793
COVID-19 Fiocruz Genomic Surveillance Network
Fundação Oswaldo Cruz · BRSecretaria da Saúde · BRFundação Carlos Chagas · BRHokkaido University · JP

Funding

Lacrimal Gland Repair Using Progenitor CellsR01EY026202 · NEI · SCRIPPS RESEARCH INSTITUTE, THE · PI MAKARENKOVA, HELEN P. · 2016 to 2025
$5.2M
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 304883/2020-4Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 306146/2017-7Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 311759/2022-0Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 313403/2018-0Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) MCTI402457/2020-0, 403276/2020-9, 423857/2021-5Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) E-26/202.896/2018Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) E26/210.196/2020, E-26/211.125/202Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) SEI-260003/019669/2022Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) 01.02.016301.00439/2023-70Fundação Oswaldo Cruz (FIOCRUZ) VPPCB-005-FIO-20-2, VPPCB-007-FIO-18-2-30HHS | Centers for Disease Control and Prevention (CDC) 002174United States Agency for International Development (USAID) 7200AA19CA00015
6 · The paper itself

Abstract

The SARS-CoV-2 XBB is a group of highly immune-evasive lineages of the Omicron variant of concern that emerged by recombining BA.2-descendent lineages and spread worldwide during 2023. In this study, we combine SARS-CoV-2 genomic data ( IMPORTANCE: Brazil was one the most affected countries by the SARS-CoV-2 pandemic, with more than 700,000 deaths by mid-2023. This study reconstructs the dissemination of the virus in the country in the first half of 2023, a period characterized by the dissemination of descendants of XBB.1, a recombinant of Omicron BA.2 lineages evolved in late 2022. The analysis supports that XBB dissemination was marked by the continuous emergence of indigenous lineages bearing similar mutations in key sites of their Spike protein, a process followed by continuous increments in transmissibility, and without repercussions in the incidence of severe cases. Thus, the results suggest that the epidemiological impact of the spread of a SARS-CoV-2 variant is influenced by an intricate interplay of factors that extend beyond the virus's transmissibility alone. The study also underlines the need for SARS-CoV-2 genomic surveillance that allows the monitoring of its ever-shifting composition.

Indexed as

COVID-19BrazilHumansSARS-CoV-2Spike Glycoprotein, CoronavirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2BrazilphylogeographySARISARS-CoV-2XBB

Identifiers

PMID38315011
PMCPMC10913747
OpenAlexW4391540925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.